QUENTIN CHAMBERS: Open Payments
NPI 1750794319 · DES MOINES, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,623 in 104 payments from 12 companies in 2025. Trend: 2023 $1,044 · 2024 $1,639 · 2025 $2,623
Food & beverage: $2,619Education: $4
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 18 | $584 |
| Alkermes, Inc. | 11 | $469 |
| Vanda Pharmaceuticals Inc. | 12 | $395 |
| E.R. Squibb & Sons, L.L.C. | 23 | $326 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $229 |
| Teva Pharmaceuticals USA, Inc. | 11 | $202 |
| Otsuka America Pharmaceutical, Inc. | 10 | $142 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $105 |
| ABBVIE INC. | 3 | $78 |
| Supernus Pharmaceuticals, Inc. | 3 | $53 |
Products named: INGREZZA, FANAPT, COBENFY, LYBALVI, CAPLYTA, ARISTADA, REXULTI, AUSTEDO XR.
Industry payments across IA — which companies pay providers there.
